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Abstract
Background: Cytoreduction followed by hyperthermic intraperitoneal chemotherapy (HIPEC)
improves survival in patients with peritoneal carcinomatosis of colorectal origin. Animal models are
important in the evaluation of new treatment modalities. The purpose of this study was to devise
an experimental setting which can be routinely used for the investigation of HIPEC in peritoneal
carcinomatosis.
Methods: A new peritoneal perfusion system in tumor bearing rats were tested. For this purpose
CC531 colon carcinoma cells were implanted intraperitoneally in Wag/Rija rats. After 10 days of
tumor growth the animals were randomized into three groups of six animals each: group 1: control
(n = 6), group 2: HIPEC with mitomycin C in a concentration of 15 mg/m2 (n = 6), group III:
mitomycin C i.p. as monotherapy in a concentration of 10 mg/m2 (n = 6). After 10 days, total tumor
weight and the extent of tumor spread, as classified by the modified Peritoneal Cancer Index (PCI),
were assessed by autopsy of the animals.
Results: No postoperative deaths were observed. Conjunctivitis, lethargy and loss of appetite
were the main side effects in the HIPEC group. No severe locoregional or systemic toxity was
observed. All control animals developed massive tumor growth. Tumor load was significantly
reduced in the treatment group and was lowest in group II.
Conclusion: The combination of hyperthermia with MMC resulted in an increased tumoricidal
effect in the rat model. The presented model provides an opportunity to study the mechanism and
effect of hyperthermic intraperitoneal chemotherapy and new drugs for this treatment modality.
Background
Peritoneal carcinomatosis (PC) represents an advanced
form of cancer and is associated with a poor prognosis
and quality of life. The peritoneal failure rate among
patients who present with recurrence after colon cancer
resection is approximately 25–35% [1]. The median sur-
vival time after manifestation of peritoneal carcinomato-
sis is about 6 months. If peritoneal carcinomatosis is
present, normaly there is no curative treatment available
for any of the tumors in the abdominal cavity.
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Hyperthermic intraperitoneal chemotherapy (HIPEC) is a
new treatment modality. Complete cytoreductive surgery
plus HIPEC is effective in the prevention and treatment of
peritoneal metastases and it should lead to long-term sur-
vival for serosa-invasive carcinoma patients [2]. The effi-
cacy of intraperitoneal (i.p.) chemotherapy is
synergistically by hyperthermia. Although the technique
of hyperthermic intraperitoneal chemoperfusion in
humans has been employed in cancer therapy, controlled
studies using this approach are rare. Intraperitoneal chem-
otherapy results in a high local drug concentration with
less systemic exposure compared to conventional i.v. drug
administration [3,4]. Peritoneal lavage with mitomycin C
(MMC) results in a drug exposure of the peritoneal surface
that is 20 times higher than elsewhere in the body [5,6].
The additional toxic effect of MMC at temperatures higher
than 39°C has been demonstrated both in animals and in
in vitro models [7,8].
One disadvantage of HIPEC is the limited penetration
depth of cytostatic drugs into the tissue [4]. Thus, HIPEC
must be combined with cytoreductive surgery. However,
complex surgical techniques in an experimental setting
should be comparable to the clinical situation. We there-
fore developed a miniaturised animal model and here-
with report the details of the design and its efficiency.
Methods
Animals
18 inbred male pathogen-free WAG/Rija rats weighing
200 to 240 g, obtained from Charles River, Sulzfeld, Ger-
many, were used in this study. The animals were kept in
individual cages during the experiment and 12 hours of
light per day. They were fed a standard laboratory diet and
tap water ad libidum. Maintenance and care of all experi-
mental animals were carried out according to the guide-
lines of the local responsible Animal Protection
Commission and carried out in compliance with national
guidelines (National Institute of Health for Use of Labo-
ratory Animals).
Tumor
The tumor cell line used was a moderately differentiated
adenocarcinoma of the rat colon (tumor cell line CC531;
1,2-dimithylhydrazine-induced [9]) obtained from the
German Cancer Research Centre, Heidelberg, Germany.
Intraperitoneal tumor application was performed with a
tumor suspension produced in vitro. The tumor cell line
was cultivated at 37°C and 5% CO2 in monolayer cultures
in an incubator in 20 ml complete medium (RPMI 1640
[Gibco, Life Technologies, Eggenstein, Germany], 10%
heat-inactivated fetal bovine serum [Seromed, Biochrom,
Berlin, Germany] and 1% Pen/Strep [Seromed]). After
three days, cells were washed twice with phosphate buff-
ered saline (PBS) and were detached with 3 ml trypsin
(0.25 %). Trypsin was deactivated by adding the complete
medium. After centrifugation, washing and re-suspension
with PBS, vitality was evaluated in a Bürker hematocytom-
eter after the addition of trypan blue. After vital counting,
the suspension had a density of 2,5 × 106 vital cells/200 µl
suspension (after centrifugation and re-suspension in
PBS) before being injected into the animals. To control for
possible mutations of cell lines, only cultures that had
undergone less than 10 passages were used in the
experiments.
The tumor cells were implanted via laparotomy per-
formed under general anesthesia. The rats were anaesthe-
tized by using isoflurane. The abdomen was shaved and
cleaned with 70% alcohol. The laparotomy was per-
formed using a lower middle incision of 6 cm. The tumor
cell suspension was injected under the capsule of the peri-
toneal surface in the right upper side of the abdomen.
Hence, tumor size and localisation were comparable to
the human situation, especially after extensive cytoreduc-
tive surgery (Fig 3).
The animals were randomised into three groups of six ani-
mals each: group 1: control (n = 6), and group 2: HIPEC
with MMC in a concentration of 15 mg/m2 (n = 6), group
3: MMC i.p. in a concentration of 10 mg/m2 (n = 6).
The equipment consisted of a miniature heat exchanger
and a roller pump. The peritoneal perfusate was warmed
in the heat exchanger (which consists of two outer silicone
tubes with diameter of 15 mm for the in- and out-flowing
water (Fig. 1)). The warmed perfusate was driven by a
roller pump with two synchronously running pump-
heads on a single axis for the inflow and the outflow lines
(Masterflex®).
The intraperitoneal temperature was maintained between
40.5 and 41.5°C. Perfusion was performed over 90 min-
utes after the perfusion fluid had reached the required
temperature. In group II, mitomycin C was added to the
perfusate in three divided doses at 30 min intervals in a
drug concentration of 15 mg/m2. The body surface of the
animals was calculated according the formula (A(m2) =
mk
0,425 × 1K
0,725/139.315). The first dose contained 50%
and the following administrations 25% of the total dose.
For temperature measurement during perfusion, a nickel-
chrome-nickel thermocouple of 0.6 mm in diameter
(Standard Integrated Thermocouple Thermocoax, Phil-
lips, Hamburg, Germany) was placed near the macro-
scopic tumor margin. Temperature was also monitored in
the rectal cavity. The thermocouple was calibrated before
use in a high-precision water bath. Baseline temperature
was recorded for 5 minutes before treatment. TemperatureBMC Cancer 2005, 5:56 http://www.biomedcentral.com/1471-2407/5/56
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was continuously measured during application. In group
I (control) and group III (MMC only) temperature meas-
urement was not performed.
After the perfusion the perfusate was removed and the
abdomen was irrigated with saline for 10 minutes. There-
after the abdomen was closed in two layers.
Evaluation
All animals were kept in individual cages. The rats were
weighed and inspected for side effects (lethargy, loss of
appetite, fatigue syndrome, wound infection) daily. The
animals were kept under standard conditions and were
euthanised by an overdose of anesthetic and cervical dis-
location 10 days after treatment.
The animals were autopsied and peritoneal carcinomato-
sis was evaluated qualitatively and quantitatively. The
tumor nodules were counted macroscopically.
Tumor response
Tumor response was graded according to the classification
system as described by Steller et al. [10]. The scoring
ranged from 0 to 5 and was performed by 2 independent
observers. A score of 0 meant that there was no tumor
growth; a score of 1 indicated an estimated tumor diame-
ter less than 0.5 cm; a score of 2, a tumor diameter
between 0.5 and 1 cm; a score of 3, a tumor diameter
between 1 and 2 cm; a score of 4, a tumor diameter
between 2 and 3 cm; and a score of 5, a tumor diameter of
more than 3 cm.
Diagram of the experimental HIPEC circuit Figure 1
Diagram of the experimental HIPEC circuit.
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Statistical Analysis
Data were analyzed using SPSS/PC+ statistical software.
The mean scores were calculated. The significance of dif-
ferences was assessed by the Kruskal-Wallis-test. A p value
< 0.05 was considered to be significant.
Results
All animals survived the operative procedure and could be
evaluated 10 days following surgery. No unexpected death
occured after surgery.
Perfusion characteristics
Intraoperatively the required tissue temperature was
reached within 9–11 minutes in the HIPEC group. Stable
temperatures were then maintained for a further 90 min-
utes with a mean of 40.4°C ± 0.5. The volume needed to
fill the perfusion circuit was about 250 ml. To reach tissue
temperature the perfusion fluid was maintained at 45,3°C
± 2.3. The calculated body surface of the animals was
0.03–0.04 m2.
The course of intraperitoneal and rectal temperatures are
presented in Fig. 2.
Duration of the procedure
The operation time, including the time needed to install
the perfusion circuit, varied from 112 to 135 min (mean
121) in group II.
Body weight
Postoperatively body weight decreased in all groups dur-
ing the first 5 days with a maximum decrease of 5 per cent.
The temperature course during HIPEC in the abdomen and  in the rectal cavity Figure 2
The temperature course during HIPEC in the abdomen and 
in the rectal cavity.
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Limited tumor implantation Figure 3
Limited tumor implantation. Injection of cell suspension 
under the capsule of the peritoneal surface preventing diffuse 
peritoneal carcinomatosis (a). Isolated tumour nodule with-
out diffuse carcinoses 10 days after implantation (b). Repre-
sentative gross sections of peritoneal carcinomatosis in 
group I (control), II (HIPEC) and group III (MMC only) 10 
days postoperatively.BMC Cancer 2005, 5:56 http://www.biomedcentral.com/1471-2407/5/56
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In the following 3 days, body weight recovered up to 108
percent of the pre-operative level. No significant differ-
ences were found between the experimental groups.
Clinical appearance
Conjunctivitis, lethargy and loss of appetite were the main
side effects observed in each of the treatment groups.
These were particulary pronounced in the HIPEC group.
After 10 days 4/6 animals in group II had minor bleeding
in the peritoneum. Moderate toxic reactions of the perito-
neum were found in two animals in group III (MMC i.p.).
Control animals had no side effects in the gastrointestinal
tract.
Macroscopic tumor growth
In group I, all animals developed extensive intraperito-
neal tumor growth. The median tumor weight was 8,1 ±
3,4 g. In group II and III median tumor weight was 1,8 ±
0,9 g and 5,7 ± 2,4 g. The cancer indices were significantly
lower in group III (2,6) than in group I (3,5). The lowest
tumor load was observed in group II (1,4). Tumor nod-
ules in group II were 4 ± 2. Tumor nodules in group II
were significant more after 10 days (35 ± 12) The tumor
scores are given in table 1.
In group I, liver metastases were observed in two of the
rats.
Discussion
Hyperthermic intraperitoneal chemotherapy (HIPEC)
with mitomycin C has been applied following cytoreduc-
tive surgery for various peritoneal surface malignancies.
Spratt et al. first performed HIPEC in a patient with pseu-
domyxoma peritonei [11]. A significant survival benefit
has been shown for HIPEC when compared to systemic
chemotherapy alone [4]. The complete cytoreductive
surgery is the most important prognostic factor. Incom-
plete cytoreduction results in limited survival [12,13].
The goal of this study was to investigate the feasibility of
HIPEC surviving tumor-bearing rats model and to investi-
gate the efficacy of HIPEC applied to a single tumor grow-
ing intraperitoneally.
Hyperthermia and drugs used during HIPEC procedures
have a limited penetration depth [14,4]. Therefore, HIPEC
can only be effective in patients with minimal residual
disease after extensive cytoreductive surgery. In the major-
ity of related animal studies, tumor cells were injected
directly into the abdominal cavity. This procedure results
in diffuse growth of peritoneal carcinomatosis. To simu-
late cytoreductive surgery in our animal model, the
CC531 colon carcinoma was implanted in an intraperito-
nael fat pad as described by Veenhuizen et al. [15]. Using
this technique, we prevented diffuse tumor spread in the
abdominal cavity. This technique may better simulate the
clinical situation after de-bulking. The development of the
tumors was 100 %. In contrast, Los described that only
80% of rats developed carcinomatosis after i.p. inocula-
tion [3,4].
HIPEC could be conducted without difficulty in all cases.
None of the animals died during perfusion. During and
after 10 days following intervention, no serious complica-
tions were observed. In contrast to the control group (no
treatment), there were 3 cases of mild side effects in group
II. However, all of these side effects were completely
reversible after a few days. During the procedure the
abdominal cavity was kept open, allowing the abdominal
perfusate to be stirred, resulting in a more homogeneous
distribution of heated drug solution throughout the entire
abdominal cavity.
The fact that an average temperature (of the perfusate) of
45,6°C was required in order to ensure the necessary
intraabdominal temperature of 40,5°C, demonstrates the
high degree of cooling that occurred across the large
surface area. This question the feasibility of a closed abdo-
men procedure, which has been both postulated and clin-
ically practised. An additional benefit of such a procedure
would be a reduction of the potential MMC exposure risk
for the operating staff. However, a major concern associ-
ated with a closed abdominal procedure is the
inhomogenous distribution of the cytostatic drug and the
intraabdominal temperature, because the abdominal
peritoneal perfusate cannot be manually stirred as in open
perfusion. A homogenous distribution of temperature is
Table 1: Objective tumor response in groups 1 (control; n = 6), 2 (HIPEC; n = 6), and 3 (MMC only; n = 6) 10 days after intervention. * 
P < 0.05 versus groups 1 and 3; § P < 0.05 versus group 1 (Kruskal-Wallis test)
Group I Group II Group III
Tumor weight (g) 8,1 ± 3,4 1,8 ± 0,9 * 5,7 ± 2,4 §
Tumor nodules 35 ± 12 4 ± 2 * 16 ± 10 §
Cancer index 3,5 1,4 * 2,6
Ascites 2/6 0/6 0/6
Clinical CR 0/6 4/6 1/6BMC Cancer 2005, 5:56 http://www.biomedcentral.com/1471-2407/5/56
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reliably assured by the open approach only, together with
measurement of the temperature directely at the tumor,
i.e. the target site.
MMC was chosen as the chemotherapeutic agent because
of its known direct cytotoxic effect in the treatment of
colorectal cancer and the thermal enhancement of its
activity [16]. Heated intraperitoneal MMC is used in the
clinical HIPEC setting with a concentration of 30–35 mg/
m2 [17]. This concentration is 50 % higher than the max-
imum tolerated intravenous dose of MMC (20 mg/m2)
because HIPEC results in decreased drug absorption from
the perfusate (approx. 70%) [5]. Compared to the clinical
situation, the MMC ratio in our experimental trial was
1,5:1 (HIPEC versus i.p. therapy). In animal models,
MMC proved highly potent in the experimental setting
and completely prevented intraperitoneal tumor growth
in the maximal tolerated dosis of 20 mg/m2 i.p. [18]. In
comparison, the MMC concentrations chosen for the
study were lower than the maximal tolerated dose, but
also administered in a ratio of 1,5:1 (15 mg/m2 HIPEC
versus 10 mg/m2 i.p.). Our results showed that MMC con-
centration of 10 mg/m2 was not effective enough to com-
pletely inhibit tumor growth in group III (therapy of solid
tumor) in contrast to the study of HRIBASCHEK et al.
(preventing of peritoneal carcinomatosis)(18).
Primary results regarding tumor response in this HIPEC
animal model confirm the clinical data collected thus far.
In comparison to the control group, a significant delay of
tumor growth was demonstrated in group III. This shows
that MMC, as a monotherapy, has a clear influence on
tumor response. The fact that tumor growth was merely
slowed (but not arrested) demonstrates that the chosen
MMC concentration was not too high.
Diffuse intraperitoneal tumor spread in the control group  (group I) Figure 4
Diffuse intraperitoneal tumor spread in the control group 
(group I).
Small tumor load in HIPEC group (group II) Figure 5
Small tumor load in HIPEC group (group II).BMC Cancer 2005, 5:56 http://www.biomedcentral.com/1471-2407/5/56
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Conclusion
By the presented model, the procedure of HIPEC could be
evaluated qualitatively and quantitatively. The direct
effect of HIPEC could be recorded macroscopically. Long-
term observations can be conducted without difficulty,
assuming acceptable mortality and morbidity rates.
In conclusion, intraperitoneal macroscopic tumor growth
was reduced after hyperthermic intraperitoneal chemop-
erfusion in comparison with MMC application alone.
However, further experimental in vitro and in vivo studies
are required to better charaterize the exact mechanism of
HIPEC and to set up objective parameters for optimiza-
tion of the procedure.
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